- Hidalgo-Sastre A.
- Brodylo R.L.
- Lubeseder-Martellato C.
- Sipos B.
- Steiger K.
- Lee M.
- von Figura G.
- Grunwald B.
- Zhong S.
- Trajkovic-Arsic M.
- Neff F.
- Schmid R.M.
- Siveke J.T.
- Ozdemir B.C.
- Pentcheva-Hoang T.
- Carstens J.L.
- Zheng X.
- Wu C.C.
- Simpson T.R.
- Laklai H.
- Sugimoto H.
- Kahlert C.
- Novitskiy S.V.
- De Jesus-Acosta A.
- Sharma P.
- Heidari P.
- Mahmood U.
- Chin L.
- Moses H.L.
- Weaver V.M.
- Maitra A.
- Allison J.P.
- LeBleu V.S.
- Kalluri R.
- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
- Sherman M.H.
- Yu R.T.
- Engle D.D.
- Ding N.
- Atkins A.R.
- Tiriac H.
- Collisson E.A.
- Connor F.
- Van Dyke T.
- Kozlov S.
- Martin P.
- Tseng T.W.
- Dawson D.W.
- Donahue T.R.
- Masamune A.
- Shimosegawa T.
- Apte M.V.
- Wilson J.S.
- Ng B.
- Lau S.L.
- Gunton J.E.
- Wahl G.M.
- Hunter T.
- Drebin J.A.
- O'Dwyer P.J.
- Liddle C.
- Tuveson D.A.
- Downes M.
- Evans R.M.
- Ozdemir B.C.
- Pentcheva-Hoang T.
- Carstens J.L.
- Zheng X.
- Wu C.C.
- Simpson T.R.
- Laklai H.
- Sugimoto H.
- Kahlert C.
- Novitskiy S.V.
- De Jesus-Acosta A.
- Sharma P.
- Heidari P.
- Mahmood U.
- Chin L.
- Moses H.L.
- Weaver V.M.
- Maitra A.
- Allison J.P.
- LeBleu V.S.
- Kalluri R.
- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
- Sherman M.H.
- Yu R.T.
- Engle D.D.
- Ding N.
- Atkins A.R.
- Tiriac H.
- Collisson E.A.
- Connor F.
- Van Dyke T.
- Kozlov S.
- Martin P.
- Tseng T.W.
- Dawson D.W.
- Donahue T.R.
- Masamune A.
- Shimosegawa T.
- Apte M.V.
- Wilson J.S.
- Ng B.
- Lau S.L.
- Gunton J.E.
- Wahl G.M.
- Hunter T.
- Drebin J.A.
- O'Dwyer P.J.
- Liddle C.
- Tuveson D.A.
- Downes M.
- Evans R.M.
- Ambrogio C.
- Gomez-Lopez G.
- Falcone M.
- Vidal A.
- Nadal E.
- Crosetto N.
- Blasco R.B.
- Fernandez-Marcos P.J.
- Sanchez-Cespedes M.
- Ren X.
- Wang Z.
- Ding K.
- Hidalgo M.
- Serrano M.
- Villanueva A.
- Santamaria D.
- Barbacid M.
Materials and Methods
Mouse Models
- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
- Hingorani S.R.
- Petricoin E.F.
- Maitra A.
- Rajapakse V.
- King C.
- Jacobetz M.A.
- Ross S.
- Conrads T.P.
- Veenstra T.D.
- Hitt B.A.
- Kawaguchi Y.
- Johann D.
- Liotta L.A.
- Crawford H.C.
- Putt M.E.
- Jacks T.
- Wright C.V.
- Hruban R.H.
- Lowy A.M.
- Tuveson D.A.
Cell Culture
Cerulein Treatment
IHC, Immunofluorescence, and Quantification
Antibody | Company | Catalog no. | Concentration | Method |
---|---|---|---|---|
DDR1 (C-20) | Santa Cruz Biotechnology, Dallas, TX | sc532 | 1:250 | Human tissue microarray |
DDR1 (D16G) XP | Cell Signaling Technologies, Danvers, MA | 5583 | 1:250 1:1000 | Immunofluorescence Western blot |
Ki-67 | Abcam, Cambridge, United Kingdom | ab15580 | 1:1000 | Immunohistochemistry |
Cleaved caspase 3 | Cell Signaling Technologies | 9664 | 1:200 | Immunohistochemistry |
Phosphohistone H3 (Ser10) | Cell Signaling Technologies | 9701 | 1:100 | Immunohistochemistry and immunofluorescence |
Amylase | Sigma, St. Louis, MO | A8273 | 1:1000 | Immunohistochemistry |
Amylase | Santa Cruz | sc12821 | 1:250 | Immunofluorescence |
Cytokeratin 19 | TROMA, Long Island, NY | Max Plank | 1:1000 | Immunohistochemistry |
E-cadherin | BD Pharmingen, Franklin Lakes, NJ | 610182 | 1:100 | Immunofluorescence |
P21 | Santa Cruz | sc471 | 1:100 | Immunohistochemistry |
DDR2 | Cell Signaling Technologies | 12133 | 1:1000 | Western blot |
Collagen 1a | Abcam | Ab34710 | 1:250 | Immunohistochemistry |
Collagen 1a | Millipore, Burlington, MA | Ab765p | 1:1000 | Western blot |
α-Smooth muscle actin | Abcam | Ab5694 | 1:20,000 | Western Blot |
Podoplanin (biotinylated) | BioLegend, San Diego, CA | 127403 | 1:100 | Immunofluorescence |
Immunoblotting
Second Harmonic Generation (SHG) of Polarized Light Microscopy
Pathologic Analysis
Statistical Analysis
Results
DDR1 Is Expressed in Tumor Epithelia in Human PDA and Murine Models of PDA

- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
DDR1 Promotes Tumor Growth and Progression

Genotype | Tumors, n | ||
---|---|---|---|
Well differentiated | Moderately differentiated | Poorly differentiated | |
KPC | 0 | 3 | 3 |
Ddr1−/−; KPC | 3 | 3 | 1 |

DDR1 Ablation Induces Tissue Atrophy in Early Pancreatic Neoplasia
- Hingorani S.R.
- Petricoin E.F.
- Maitra A.
- Rajapakse V.
- King C.
- Jacobetz M.A.
- Ross S.
- Conrads T.P.
- Veenstra T.D.
- Hitt B.A.
- Kawaguchi Y.
- Johann D.
- Liotta L.A.
- Crawford H.C.
- Putt M.E.
- Jacks T.
- Wright C.V.
- Hruban R.H.
- Lowy A.M.
- Tuveson D.A.
- Hingorani S.R.
- Petricoin E.F.
- Maitra A.
- Rajapakse V.
- King C.
- Jacobetz M.A.
- Ross S.
- Conrads T.P.
- Veenstra T.D.
- Hitt B.A.
- Kawaguchi Y.
- Johann D.
- Liotta L.A.
- Crawford H.C.
- Putt M.E.
- Jacks T.
- Wright C.V.
- Hruban R.H.
- Lowy A.M.
- Tuveson D.A.

- Ardito C.M.
- Gruner B.M.
- Takeuchi K.K.
- Lubeseder-Martellato C.
- Teichmann N.
- Mazur P.K.
- Delgiorno K.E.
- Carpenter E.S.
- Halbrook C.J.
- Hall J.C.
- Pal D.
- Briel T.
- Herner A.
- Trajkovic-Arsic M.
- Sipos B.
- Liou G.Y.
- Storz P.
- Murray N.R.
- Threadgill D.W.
- Sibilia M.
- Washington M.K.
- Wilson C.L.
- Schmid R.M.
- Raines E.W.
- Crawford H.C.
- Siveke J.T.
- Ardito C.M.
- Gruner B.M.
- Takeuchi K.K.
- Lubeseder-Martellato C.
- Teichmann N.
- Mazur P.K.
- Delgiorno K.E.
- Carpenter E.S.
- Halbrook C.J.
- Hall J.C.
- Pal D.
- Briel T.
- Herner A.
- Trajkovic-Arsic M.
- Sipos B.
- Liou G.Y.
- Storz P.
- Murray N.R.
- Threadgill D.W.
- Sibilia M.
- Washington M.K.
- Wilson C.L.
- Schmid R.M.
- Raines E.W.
- Crawford H.C.
- Siveke J.T.

DDR1 Is Necessary for Tissue Regeneration after Experimental Pancreatitis


- Elyada E.
- Bolisetty M.
- Laise P.
- Flynn W.F.
- Courtois E.T.
- Burkhart R.A.
- Teinor J.A.
- Belleau P.
- Biffi G.
- Lucito M.S.
- Sivajothi S.
- Armstrong T.D.
- Engle D.D.
- Yu K.H.
- Hao Y.
- Wolfgang C.L.
- Park Y.
- Preall J.
- Jaffee E.M.
- Califano A.
- Robson P.
- Tuveson D.A.

Discussion
- Ozdemir B.C.
- Pentcheva-Hoang T.
- Carstens J.L.
- Zheng X.
- Wu C.C.
- Simpson T.R.
- Laklai H.
- Sugimoto H.
- Kahlert C.
- Novitskiy S.V.
- De Jesus-Acosta A.
- Sharma P.
- Heidari P.
- Mahmood U.
- Chin L.
- Moses H.L.
- Weaver V.M.
- Maitra A.
- Allison J.P.
- LeBleu V.S.
- Kalluri R.
- Rhim A.D.
- Oberstein P.E.
- Thomas D.H.
- Mirek E.T.
- Palermo C.F.
- Sastra S.A.
- Dekleva E.N.
- Saunders T.
- Becerra C.P.
- Tattersall I.W.
- Westphalen C.B.
- Kitajewski J.
- Fernandez-Barrena M.G.
- Fernandez-Zapico M.E.
- Iacobuzio-Donahue C.
- Olive K.P.
- Stanger B.Z.
- Ozdemir B.C.
- Pentcheva-Hoang T.
- Carstens J.L.
- Zheng X.
- Wu C.C.
- Simpson T.R.
- Laklai H.
- Sugimoto H.
- Kahlert C.
- Novitskiy S.V.
- De Jesus-Acosta A.
- Sharma P.
- Heidari P.
- Mahmood U.
- Chin L.
- Moses H.L.
- Weaver V.M.
- Maitra A.
- Allison J.P.
- LeBleu V.S.
- Kalluri R.
- Sherman M.H.
- Yu R.T.
- Engle D.D.
- Ding N.
- Atkins A.R.
- Tiriac H.
- Collisson E.A.
- Connor F.
- Van Dyke T.
- Kozlov S.
- Martin P.
- Tseng T.W.
- Dawson D.W.
- Donahue T.R.
- Masamune A.
- Shimosegawa T.
- Apte M.V.
- Wilson J.S.
- Ng B.
- Lau S.L.
- Gunton J.E.
- Wahl G.M.
- Hunter T.
- Drebin J.A.
- O'Dwyer P.J.
- Liddle C.
- Tuveson D.A.
- Downes M.
- Evans R.M.
- Hingorani S.R.
- Harris W.P.
- Beck J.T.
- Berdov B.A.
- Wagner S.A.
- Pshevlotsky E.M.
- Tjulandin S.A.
- Gladkov O.A.
- Holcombe R.F.
- Korn R.
- Raghunand N.
- Dychter S.
- Jiang P.
- Shepard H.M.
- Devoe C.E.
- Ambrogio C.
- Gomez-Lopez G.
- Falcone M.
- Vidal A.
- Nadal E.
- Crosetto N.
- Blasco R.B.
- Fernandez-Marcos P.J.
- Sanchez-Cespedes M.
- Ren X.
- Wang Z.
- Ding K.
- Hidalgo M.
- Serrano M.
- Villanueva A.
- Santamaria D.
- Barbacid M.
- Ambrogio C.
- Gomez-Lopez G.
- Falcone M.
- Vidal A.
- Nadal E.
- Crosetto N.
- Blasco R.B.
- Fernandez-Marcos P.J.
- Sanchez-Cespedes M.
- Ren X.
- Wang Z.
- Ding K.
- Hidalgo M.
- Serrano M.
- Villanueva A.
- Santamaria D.
- Barbacid M.
- Sherman M.H.
- Yu R.T.
- Engle D.D.
- Ding N.
- Atkins A.R.
- Tiriac H.
- Collisson E.A.
- Connor F.
- Van Dyke T.
- Kozlov S.
- Martin P.
- Tseng T.W.
- Dawson D.W.
- Donahue T.R.
- Masamune A.
- Shimosegawa T.
- Apte M.V.
- Wilson J.S.
- Ng B.
- Lau S.L.
- Gunton J.E.
- Wahl G.M.
- Hunter T.
- Drebin J.A.
- O'Dwyer P.J.
- Liddle C.
- Tuveson D.A.
- Downes M.
- Evans R.M.
- Franco-Barraza J.
- Francescone R.
- Luong T.
- Shah N.
- Madhani R.
- Cukierman G.
- Dulaimi E.
- Devarajan K.
- Egleston B.L.
- Nicolas E.
- Katherine Alpaugh R.
- Malik R.
- Uzzo R.G.
- Hoffman J.P.
- Golemis E.A.
- Cukierman E.
Supplemental Data






References
- Cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 7-30
- Molecular subtypes of pancreatic cancer.Nat Rev Gastroenterol Hepatol. 2019; 16: 207-220
- Therapeutic developments in pancreatic cancer: current and future perspectives.Nat Rev Gastroenterol Hepatol. 2018; 15: 333-348
- Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy.Gastroenterology. 2007; 132: 1557-1573
- In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia.Gastroenterology. 2007; 133: 1999-2009
- Preexisting pancreatic acinar cells contribute to acinar cell, but not islet beta cell, regeneration.J Clin Invest. 2007; 117: 971-977
- Hes1 controls exocrine cell plasticity and restricts development of pancreatic ductal adenocarcinoma in a mouse model.Am J Pathol. 2016; 186: 2934-2944
- Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.Cancer Cell. 2012; 22: 737-750
- Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy.Eur Surg. 2019; 51: 126-134
- Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project.Gut. 2012; 61: 1085-1094
- Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.Cancer Cell. 2007; 11: 291-302
- Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer.Am J Physiol Gastrointest Liver Physiol. 2018; 315: G27-G35
- Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.Cancer Cell. 2012; 21: 418-429
- Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.Science. 2009; 324: 1457-1461
- Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.Cancer Cell. 2014; 25: 719-734
- Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.Cancer Cell. 2014; 25: 735-747
- Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.Cell. 2014; 159: 80-93
- Discoidin domain receptor functions in physiological and pathological conditions.Int Rev Cell Mol Biol. 2014; 310: 39-87
- Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis.Am J Respir Crit Care Med. 2006; 174: 420-427
- Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy.Am J Pathol. 2011; 179: 83-91
- Discoidin domain receptor 1 (Ddr1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers.Genes Dev. 2018; 32: 244-257
- Combined inhibition of Ddr1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Nat Med. 2016; 22: 270-277
- Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma.Mol Cancer Ther. 2017; 16: 2473-2485
- The discoidin domain receptor tyrosine kinase DDR1 in arterial wound repair.J Clin Invest. 2001; 107: 727-735
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.Cancer Cell. 2003; 4: 437-450
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.Cancer Cell. 2005; 7: 469-483
- Mitogen-activated protein kinase kinase activity maintains acinar-to-ductal metaplasia and is required for organ regeneration in pancreatitis.Cell Mol Gastroenterol Hepatol. 2017; 3: 99-118
- Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease.J Am Soc Nephrol. 2006; 17: 3374-3381
- Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis.Mol Cancer. 2019; 18: 14
- EGF receptor is required for KRAS-induced pancreatic tumorigenesis.Cancer Cell. 2012; 22: 304-317
- Single-cell analysis uncovers clonal scinar cell heterogeneity in the adult pancreas.Dev Cell. 2016; 39: 289-301
- Myeloid cell-derived HB-EGF drives tissue recovery after pancreatitis.Cell Mol Gastroenterol Hepatol. 2019; 8: 173-192
- Podoplanin: emerging functions in development, the immune system, and cancer.Front Immunol. 2012; 3: 283
- Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts.Cancer Discov. 2019; 9: 1102-1123
- The extracellular matrix and pancreatic cancer: a complex relationship.Cancers (Basel). 2018; 10: 316
- Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma.Cancers (Basel). 2018; 10: 193
- ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion.Nat Commun. 2016; 7: 12630
- Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer.Clin Cancer Res. 2016; 22: 2848-2854
- Why HALO 301 failed and implications for treatment of pancreatic cancer.Pancreas (Fairfax). 2019; 3: e1-e4
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Nat Med. 2016; 22: 851-860
- Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.Int J Gastrointest Cancer. 2003; 34: 121-128
- The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.Clin Gastroenterol Hepatol. 2008; 6: 1155-1161
- Matrix-regulated integrin alphavbeta5 maintains alpha5beta1-dependent desmoplastic traits prognostic of neoplastic recurrence.Elife. 2017; 6: e20600
Article Info
Publication History
Footnotes
See related Commentary on page 1622
Supported by NIH grants U01CA2241145 (H.C.C. and M.P.d.M.), R50CA232985 (Y.Z.), and R21CA191347 (H.C.C and R.F.) ; Department of Defense grants CA170568 (H.C.C. and R.F.) and R21CA231252 and R01CA232256 (E.C.); Core Grants P30CA046592 (Rogel Cancer Center) and P30CA06927 (Fox Chase Cancer Center) ; a Sky Foundation development grant (H.C.C. and R.F.); Pennsylvania's Department of Health Research Formula Funds (E.C.); and the Fifth District AHEPA Cancer Research Foundation (E.C.).
Disclosures: None declared.
Identification
Copyright
User License
Elsevier user license |
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy